URGENT!!! HELP AND SUPPORT NORMAN CLEMENT vs. DEA IN US SUPREME COURT CASE NO: 22-6000
$100 $250, $500 DOLLARS SEND TO ZELLE 3135103378 OR CASH APP: $docnorm
NORMAN J CLEMENT RPH., DDS, NORMAN L.CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS MD, PH.D., C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., WALTER F. WRENN III., MD., JULIE KILLINGWORTH, LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., LEROY BAYLOR, JAY K. JOSHI MD., MBA, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
WE HAVE SEEN THIS DOG AND PONY SHOW BEFORE
Once again a pharmaceutical company is being wrongly charged with contributing to the opiate epidemic by the DOJ-DEA. They are charged with knowingly being responsible for medication being sold illegaly in the street. Think about how this is impossible. These are the steps that lead from manufacture to the streets.
An individual goes to a healthcare provider. The health care provider prescribes a opiate pain medication. The individual takes this legal prescription to the pharmacist. The pharmacist legally dispenses the medication to the individual.
However, the individual then sells the medication to another individual thus violating the law.
How was it possible for the pharmaceutical company to know this?
Walter F. Wrenn, III,M.D.
FROM NPR, NATIONAL PUBLIC RADIO:
November 21, 2021
A state judge in California ruled late Monday that four drug companies can’t be held liable for that state’s opioid epidemic. Communities had hoped for tens of billions of dollars in compensation to help ease the addiction crisis.
In his 41-page ruling, however, Judge Peter J. Wilson said it was unclear the drug industry’s marketing efforts led to directly to a rise in illegal use of prescription opioid painkillers.
The Court finds that plaintiffs have failed to prove an actionable public nuisance for which defendants, or any of them, are legally liable,” Wilson concluded. In a statement sent to NPR, a spokesperson for Johnson & Johnson praised the ruling.
The company’s “actions relating to the marketing and promotion of its important prescription pain medications were appropriate and responsible, and did not cause any public nuisance,” the statement said.
This was a significant victory for the drug industry, which faces a barrage of opioid lawsuits in state and federal courts around the country.Attorneys representing four California counties argued the drug companies Allergan, Endo, Johnson & Johnson and Teva used false and misleading marketing to push up the sale of prescription opioids. The companies denied any wrongdoing.
OCTOBER 20, 2021, PU.S.N MARCH ON WASHINGTON AMERICAN PAIN AND DISABILITY FOUNDATION
THE YEAR AND THE DATE ARE NOVEMBER 10, 2021:
“Applying the nuisance statutes to lawful products as the State requests would create unlimited and unprincipled liability for product manufacturers; this is why our Court has never applied public nuisance law to the manufacturing, marketing, and selling of lawful products,” according to the opinion.
The duty of the maker is to put lawful, non-defective products on the market, the ruling says.
“There is no common law tort duty to monitor how a consumer uses or misuses a product after it is sold,” according to the opinion. “Without control, a manufacturer cannot remove or abate the nuisance — which is the remedy the State seeks from J&J in this case.”
This ruling comes less than two weeks after a state U.S.urt judge in California sided with drug companies in another major opioid lawsuit.
Did DEA Create “FAKE” Opioid “Crisis” to Screw doctors and patients?
Millions of Americans in Agony Are Being Deserted By Doctors and Denied Pain Care
RICHARD LAWHERN Ph.D. NOVEMBER 10, 2021 WROTE For producers of NPR November 11, 2021 program segment:
“There are multiple culprits in this horror, fatally flawed and scientifically unsupported opioid guidelines of the US CDC National Center for Injury Prevention and Control have been turned into one-size-fits-all State laws restricting patient access to prescription pain relievers.
A national witch hunt of malicious prosecution and extra-legal persecution conducted by the US Drug Enforcement Agency has driven thousands of medical professionals out of practice or into prison on trumped-up charges.
The US National Academies of Medicine estimates that 50 million people suffer from moderate to severe pain every day. AsU.S. patient advocate, I talk with thousands of them in social media.
At least half of all community clinics are refusing to take new patients for the management of chronic pain.
Many remaining clinics are force-tapering patients off the only class of therapies that work safely and reliably — opioid analgesic pain relievers. (1) The practice of pain medicine in the US has effectively been destroyed. At least hundreds of desperate patients have already died of suicide.”
“DEA TAKES AN AGGRESSIVE STANCE TOWARD PHARMACIES TRYING TO DISPENSE ADDICTION MEDICINE“
NOVEMBER 8, 2021
“When Martin Njoku saw opioid addiction devastate his West Virginia community, he felt compelled to help. This was the place he’d called home for three decades, where he’d raised his two girls and turned his dream of owning a pharmacy into reality.
In 2016, after flooding displaced people in nearby counties, Njoku began dispensing buprenorphine to them and to local customers at his Oak Hill Hometown Pharmacy in Fayette County.
Buprenorphine, a controlled substance sold under the brand names Subutex and Suboxone, is a medication to treat opioid use disorder. Research shows it halves the risk of overdose and doubles people’s chances of entering long-term recovery.
“I thought I was doing what was righteous for people who have an illness,” Njoku said.
But a few years later, the Drug Enforcement Administrationraided Njoku’s pharmacy and accused the facility of contributing to the opioid epidemic rather than curbing it. The agency revoked the pharmacy’s registration to dispense controlled substances, claiming it posed an “imminent danger to public health and safety.”
JUDGE RULES IN NJOKU’S FAVOR
Although two judges separately ruled in Njoku’s favor, the DEA’s actions effectively shuttered his business.
“I lost everything that I worked for,” Njoku said.
Lawyers, pharmacists, harm-reduction advocates, and a former DEA employee say Njoku’s case is emblematic of the DEA’s aggressive stance on buprenorphine. An opioid itself, the medication can be misused, so the DEA works to limit its diversion to the streets. But many say the agency’s policies are exacerbating the opioid epidemic by scaring pharmacies away from dispensing this medication when it’s desperately needed.
Drug overdose deaths hit record highs last year, and despite medical experts considering medications like buprenorphine the gold standard, less than 20% of people with opioid use disorder typically receive them. The federal government has taken steps to increase the number of clinicians who prescribe buprenorphine, but many patients struggle to get those prescriptions filled. A recent study found that 1 in 5 U.S. pharmacies do not provide buprenorphine.
“Pharmacies are terrified they’re going to lose their DEA registration and go out of business,” said Charles “Buck” Selby, a former inspector and chief compliance officer for the West Virginia Board of Pharmacy, who retired in 2018.
MEAN WHILE IN AFGHANISTAN DEA PROTECTED POPPY PRODUCTION
FOR NOW, YOU ARE WITHIN
URGENT !!! HELP AND SUPPORT NORMAN CLEMENT vs. DEA IN US SUPREME COURT CASE NO: 22-6000 !!!
$100 $250, $500 DOLLARS SEND TO ZELLE 3135103378 OR CASH APP:$docnorm
- Mr Lasker and Ms Lu,
Washington Legal Foundation and Hollingsworth LLP
|Oklahoma Opioid Ruling: Another Instance of Improper Judicial Governance through Public Nuisance Litigation | Washington Legal FoundationBy Eric G. Lasker, a Partner, and Jessica L. Lu, an Associate, with Hollingsworth LLP in Washington, DC. Plaintiffs have long utilized the doctrine of public nuisance as a judicial avenue to force corporations to bear the costs of addressing social harms. In recent years, however, such claims have proliferated as a result of high-profile […]www.wlf.org|
This note is to share with you a letter that is being sent to all 50 US State Departments of Health and State Medical Boards. I believe that the resources offered below may be pertinent to the future activities of your firm and others in defense of major pharmaceutical firms now being vilified and persecuted by badly misinformed prosecutors and State Attorney Generals.
It is my contention that not only does public nuisance law NOT apply to prescribing of opioid analgesics to patients in pain, but the entire US and State policy concerning these issues is grounded on nothing more than junk science and deliberate distortions by financially self-interested anti-opioid zealots.
I am available by phone at 703.216.0724 Eastern Time if you would like to chat briefly about the issues raised here. My qualifications to comment are included in the text below. I can also put you in touch with an open collaborative network of highly knowledgeable medical professionals, patients and caregivers who have first-hand knowledge of the impact of irresponsible actions such as were overturned by the recent Johnson and Johnson appeal in Oklahoma